ACADIA PHARMACEUTICALS INC

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

ACAD$18.28+10.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Total stockholders’ equity, beginning balances	$1,306,609	$822,382	$1,227,390	$732,793
Common stock:
Beginning balance	16	16	16	16
Issuance of common stock from exercise of stock options and units	1	—	1	—
Ending balance	17	16	17	16
Additional paid-in capital:
Beginning balance	3,085,800	2,980,693	3,039,315	2,936,871
Issuance of common stock from exercise of stock options and units	11,870	9,423	22,613	23,943
Issuance of common stock pursuant to employee stock purchase plan	—	—	3,982	3,274
Stock-based compensation	17,471	13,105	49,231	39,133
Ending balance	3,115,141	3,003,221	3,115,141	3,003,221
Accumulated deficit:
Beginning balance	(1,778,249)	(2,158,733)	(1,813,386)	(2,204,386)
Net income	53,524	71,779	88,661	117,432
Ending balance	(1,724,725)	(2,086,954)	(1,724,725)	(2,086,954)
Other comprehensive (loss) income:
Beginning balance	(958)	406	1,445	292
Other comprehensive (loss) income	(1,986)	583	(4,389)	697
Ending balance	(2,944)	989	(2,944)	989
Total stockholders’ equity, ending balances	$1,387,489	$917,272	$1,387,489	$917,272

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.